Cargando…
Savolitinib: A Promising Targeting Agent for Cancer
SIMPLE SUMMARY: Savolitinib is a highly specific inhibitor of the MET tyrosine kinase. Both preclinical and clinical studies have shown its potential as a treatment for various cancers, including non-small cell lung cancer (NSCLC) as well as breast, head and neck, colorectal, gastric, pancreatic, an...
Autores principales: | Lee, Tae Seung, Kim, Jun Yeol, Lee, Myeong Hwan, Cho, In Rae, Paik, Woo Hyun, Ryu, Ji Kon, Kim, Yong-Tae, Lee, Sang Hyub |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571651/ https://www.ncbi.nlm.nih.gov/pubmed/37835402 http://dx.doi.org/10.3390/cancers15194708 |
Ejemplares similares
-
Efficacy and predictive factors of endoscopic ultrasound-guided ethanol ablation in benign solid pancreatic tumors
por: Choi, Jin Ho, et al.
Publicado: (2023) -
Combinatorial Effect of Prophylactic Interventions for Post-ERCP Pancreatitis among Patients with Risk Factors: A Network Meta-Analysis
por: Choi, Jin Ho, et al.
Publicado: (2023) -
DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors
por: Park, Joo Kyung, et al.
Publicado: (2017) -
High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
por: Huh, Gunn, et al.
Publicado: (2020) -
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach
por: Chun, Jung Won, et al.
Publicado: (2021)